HR, HER2 status, germline BRCA status as well as PIK3CA mutation status in HR-positive and PD-L1 in triple-negative breast cancer (TNBC) should be assessed to allow for targeted therapies. Here, CD274 is linked to triple-negative breast carcinoma.